Group 1 - The core viewpoint of the article is that China Health Technology Group reported significant revenue growth but a substantial decline in profit for the fiscal year ending June 30, 2025 [1] Group 2 - The company's revenue reached approximately 90.2 million, representing a year-on-year increase of 89.5% [1] - The profit attributable to the company's owners was about 22.7 million, showing a year-on-year decrease of 88.65% [1] - The basic earnings per share were reported at 2.75 cents [1]

Core Insights - China Health Technology Group (01069) reported annual results for the year ending June 30, 2025, with revenue of approximately 90.2 million, representing a year-on-year increase of 89.5% [1] - The profit attributable to the company's owners was approximately 22.7 million, reflecting a year-on-year decrease of 88.65% [1] - Basic earnings per share were reported at 2.75 cents [1]

Financial Performance - For the fiscal year ending June 30, 2025, the company's revenue was approximately RMB 90.2 million, a significant increase from RMB 47.6 million in the previous fiscal year[3] - The profit attributable to the owners for the fiscal year 2025 was approximately RMB 22.7 million, down from RMB 200 million in fiscal year 2024[4] - The total comprehensive income attributable to the owners for fiscal year 2025 was approximately RMB 28.2 million, compared to RMB 204 million in fiscal year 2024[4] - Basic earnings per share for fiscal year 2025 were RMB 2.75, a decrease from RMB 29.79 in fiscal year 2024[4] - The company reported a gross profit of RMB 8.2 million for fiscal year 2025, compared to RMB 1.9 million in fiscal year 2024[4] - The group reported a total profit of RMB 30,197,000 for the year ending June 30, 2025, compared to RMB 11,705,000 in the previous year, marking an increase of 157.5%[19] - The company reported a net profit of RMB 22,711,000 for 2025, a significant decrease from RMB 200,013,000 in 2024[31] Revenue Breakdown - Revenue from the timber-related products was RMB 36,633,000, up from RMB 32,521,000, indicating an increase of 34.5% year-over-year[15] - Revenue from ginseng-related products surged to RMB 39,467,000 from RMB 15,085,000, reflecting a growth of 161.5%[15] - The company’s total revenue from external customers in China reached RMB 76,100,000 in 2025, up from RMB 47,606,000 in 2024, an increase of 59.8%[25] - Ginseng business revenue reached approximately RMB 39.5 million in the 2025 fiscal year, with RMB 25 million from supplier purchases and RMB 14.5 million from self-cultivated ginseng[39] - Health product manufacturing and trading business generated revenue of approximately RMB 14.1 million in the 2025 fiscal year[40] Assets and Liabilities - The total assets less current liabilities increased to RMB 162.3 million in fiscal year 2025, up from RMB 128.9 million in fiscal year 2024[5] - The net assets of the company increased to RMB 46.7 million in fiscal year 2025, compared to RMB 12.9 million in fiscal year 2024[6] - Total assets increased to RMB 205,417,000 in 2025 from RMB 178,166,000 in 2024, representing a growth of 15.3%[22] - Total liabilities decreased to RMB 158,697,000 in 2025 from RMB 165,203,000 in 2024, a reduction of 3.1%[22] Capital Structure - The capital-to-debt ratio improved to approximately 77.3% in fiscal year 2025, down from 92.7% in fiscal year 2024, representing a decrease of 15.4 percentage points[3] - The capital-to-debt ratio as of June 30, 2025, was approximately 77.3%, a decrease from 92.7% as of June 30, 2024[57] Dividends and Share Structure - The company did not recommend any dividend distribution for fiscal year 2025, consistent with fiscal year 2024[3] - No final dividend has been recommended for the fiscal year 2025, consistent with the previous fiscal year[64] - A share consolidation was approved on July 4, 2025, reducing the total number of issued shares from 859,242,204 to 85,924,220[60] - The total number of issued shares has been adjusted from 859,242,204 to 85,924,220 following the share consolidation effective July 8, 2025[62] - The company announced a conditional placement of up to 17,000,000 new shares at a price of HKD 0.28 per share, aiming to raise approximately HKD 4.63 million, which represents an increase of about 16.52% in the enlarged issued share capital[63] Operational Developments - The company began operations in the health product trading business in November 2024, indicating a strategic expansion into new markets[8] - The group obtained harvesting permits for 18,016 cubic meters for the 2025 calendar year, an increase from the previous year's harvesting volume[41] - The group plans to gradually reduce reliance on suppliers for aged ginseng as it builds sufficient inventory of self-cultivated ginseng[41] - The group successfully planted the first batch of Epimedium on its owned land in June 2024, with an additional 28 acres planted in July 2024[42] Financial Reporting Standards - The group anticipates the adoption of new Hong Kong Financial Reporting Standards will impact its accounting policies starting from the first period after their effective date[13] - The new Hong Kong Financial Reporting Standard No. 18 will introduce new presentation and disclosure requirements in the consolidated income statement, effective from January 1, 2027[13] - The group is currently assessing the detailed impact of the new standards on its consolidated financial statements[13] - The group expects that other amendments to the Hong Kong Financial Reporting Standards will not have a significant impact on its consolidated financial statements[13] Expenses and Costs - Administrative expenses decreased by approximately 27.0% to RMB 15.7 million in fiscal year 2025, down from RMB 21.5 million in fiscal year 2024, mainly due to a reduction in legal expenses[47] - Financing costs increased by approximately 8.5% to RMB 3.5 million in fiscal year 2025, compared to RMB 3.2 million in fiscal year 2024[49] - The company incurred a total cost of RMB 36,633,000 for harvested timber in 2025, compared to RMB 32,522,000 in 2024, an increase of 12.9%[29] Trade Receivables and Payables - Trade receivables increased to RMB 33,796,000 in 2025 from RMB 17,343,000 in 2024, representing a growth of 95.5%[32] - Trade payables increased to RMB 29,029,000 in 2025 from RMB 16,304,000 in 2024, reflecting a growth of 77.6%[32] - The average credit period granted to trade customers remains at 120 days for both 2024 and 2025[32] - The average credit period for purchasing goods is maintained at 90 days[32] Audit and Compliance - The audit committee, consisting of three independent non-executive directors, reviewed the financial reporting process and internal control systems, and has no objections to the group's consolidated financial performance as reported[71]

Core Viewpoint - China Health Technology Group (01069) has entered into a non-legally binding strategic cooperation memorandum with Wuyou Health (Holdings) Group Limited to explore collaboration in community health service platform construction and health product development and sales [1] Group 1: Strategic Cooperation - The memorandum outlines a partnership aimed at leveraging Wuyou Health's market advantages and health products to explore opportunities in China's health industry [1] - The collaboration is expected to enhance the diversity of future business operations and improve profit growth for the company [1] Group 2: Market Analysis and Development - Following the signing of the memorandum, both parties will conduct market analysis and industry research related to the community health service platform and its offerings [1] - Initial activities will include personnel communication and site visits to assess health platform locations, service content, management arrangements, and product development planning [1] Group 3: Financial and Competitive Impact - The board believes that this strategic partnership will deepen the company's health business, strengthen competitiveness, and enhance financial performance and profitability [1] - The collaboration aligns with the overall interests of the company and its shareholders [1]

Core Viewpoint - China Health Technology Group (01069) has entered into a non-binding strategic cooperation memorandum with Wuyou Health (Holdings) Group Limited to collaborate on community health service platform development and health product sales [1] Group 1: Strategic Cooperation - The memorandum outlines a partnership aimed at leveraging Wuyou Health's market advantages and health products to explore opportunities in China's health industry [1] - The collaboration is expected to enhance the company's health business, diversify future operations, and improve profit growth [1] Group 2: Implementation and Analysis - Following the signing of the memorandum, both parties will conduct market analysis and industry research related to the community health service platform [1] - Initial activities will include site selection, service content planning, management arrangements, and product development [1] Group 3: Financial and Competitive Impact - The board believes that this strategic partnership will deepen the company's health business, strengthen competitiveness, and enhance financial performance and profitability [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股份代號：1069） 自願公告 戰略合作備忘錄 本公告乃由中國健康科技集團控股有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）自願作出，以告知本公司股東及潛在投資者有關本集團之最新業務發展。 戰略合作備忘錄 本公司董事（「董事」）會（「董事會」）欣然宣佈，於2025年9月26日，本公司與無憂健 康（控股）集團有限公司（「無憂健康」）訂立不具法律效力及約束力的戰略合作備 忘錄（「戰略合作備忘錄」），根據戰略合作備忘錄，雙方同意開展有關社區大健康 服務平臺建設及大健康產品開發與銷售方面的合作（「合作業務」）。 本公司為一家投資控股公司，其附屬公司主要在在中華人民共和國（「中國」）從事 林業管理業務、人參業務及健康產品業務。 無憂健康為一家在香港成立的有限公司，致力於大健康服務平臺建設，旨在於中 國內地為客戶打造便捷的綜合性健康服務平臺。 ...

Core Viewpoint - China Health Technology Group (01069.HK) announced that its board meeting will be held on September 30, 2025, to review and approve the annual performance announcement for the year ending June 30, 2025, and to consider the payment of a final dividend, if any [1] Group 1 - The board meeting is scheduled for September 30, 2025 [1] - The meeting will focus on the annual performance announcement for the fiscal year ending June 30, 2025 [1] - The board will also consider the potential payment of a final dividend [1]

中國健康科技集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董 事會（「董事會」）謹此宣佈，董事會會議將於二零二五年九月三十日（星期二）舉行， 以（其中包括）審議及批准本集團於截至二零二五年六月三十日止年度的全年業 績公告並考慮派付末期股息（如有）。 承董事會命 中國健康科技集團控股有限公司 主席兼執行董事 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股份代號：1069） 董事會會議日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 凌鋒教授 香港，二零二五年九月十八日 於本公告日期，董事會成員包括執行董事凌鋒教授、王義斌先生及畢雪女士；及獨 立非執行董事郭中隆先生、周穎楠先生及劉淑華女士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國健康科技集團控股有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01069 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 85,924,220 | | 0 | | 85,924,220 | | 增加 / 減少 (-) | | | 17,000,000 | | 0 | | | | 本月底結存 | | | 102,924,220 | | 0 | | 102,924,220 | 第 2 頁 共 10 頁 v 1.1.1 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 ...

Group 1 - The core point of the article is that China Health Technology Group (01069) has completed a share placement agreement, with 17 million shares issued at a price of HKD 0.28 per share, representing approximately 16.52% of the company's enlarged issued share capital after the placement [1] - On August 15, shareholders transferred stocks from Changli Securities to China Northern Securities Group, with a market value of HKD 2.8426 million, accounting for 5.64% [1] - The placement agreement's conditions have been fulfilled, and the placement was completed on August 1, 2025 [1]